NASDAQ:MBIO Mustang Bio (MBIO) Stock Price, News & Analysis $0.17 +0.00 (+0.73%) (As of 12:22 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Mustang Bio Stock (NASDAQ:MBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mustang Bio alerts:Sign Up Key Stats Today's Range$0.16▼$0.1750-Day Range$0.16▼$0.3152-Week Range$0.13▼$1.53Volume331,170 shsAverage Volume8.22 million shsMarket Capitalization$7.89 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingBuy Company OverviewMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Read More… Mustang Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks43rd Percentile Overall ScoreMBIO MarketRank™: Mustang Bio scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMustang Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMustang Bio has received no research coverage in the past 90 days.Read more about Mustang Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mustang Bio are expected to grow in the coming year, from ($0.70) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mustang Bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mustang Bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMustang Bio has a P/B Ratio of 16.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.58% of the float of Mustang Bio has been sold short.Short Interest Ratio / Days to CoverMustang Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mustang Bio has recently decreased by 40.36%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMustang Bio does not currently pay a dividend.Dividend GrowthMustang Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.58% of the float of Mustang Bio has been sold short.Short Interest Ratio / Days to CoverMustang Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mustang Bio has recently decreased by 40.36%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for MBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mustang Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.60% of the stock of Mustang Bio is held by insiders.Percentage Held by InstitutionsOnly 9.95% of the stock of Mustang Bio is held by institutions.Read more about Mustang Bio's insider trading history. Receive MBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address MBIO Stock News HeadlinesMustang Bio Interim CFO James Murphy ResignsNovember 16, 2024 | markets.businessinsider.comMustang Bio's Interim CFO Resigns After 10 MonthsNovember 15, 2024 | marketwatch.comA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading system finds high-probability option trades in less than 60 seconds a dayDecember 24, 2024 | Prosper Trading Academy (Ad)Mustang Bio Faces Nasdaq Delisting and Leadership ChangesNovember 15, 2024 | markets.businessinsider.comMustang Bio, Inc.: Mustang Bio Receives Positive Listing Determination from NasdaqNovember 12, 2024 | finanznachrichten.deMustang Bio Receives Positive Listing Determination from NasdaqNovember 12, 2024 | globenewswire.comMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant GliomaNovember 7, 2024 | globenewswire.comMustang Bio Secures $4M through Strategic Warrant AgreementOctober 26, 2024 | markets.businessinsider.comSee More Headlines MBIO Stock Analysis - Frequently Asked Questions How have MBIO shares performed this year? Mustang Bio's stock was trading at $1.35 at the start of the year. Since then, MBIO stock has decreased by 87.9% and is now trading at $0.1640. View the best growth stocks for 2024 here. How were Mustang Bio's earnings last quarter? Mustang Bio, Inc. (NASDAQ:MBIO) released its quarterly earnings results on Friday, November, 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.09. When did Mustang Bio's stock split? Shares of Mustang Bio reverse split on Tuesday, April 4th 2023. The 1-15 reverse split was announced on Tuesday, April 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Mustang Bio? Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mustang Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mustang Bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings11/08/2024Today12/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MBIO CUSIPN/A CIK1680048 Webwww.mustangbio.com Phone(781) 652-4500FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+1,110.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,243.22% Return on Assets-172.89% Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book16.52Miscellaneous Outstanding Shares47,780,000Free Float47,379,000Market Cap$7.89 million OptionableNot Optionable Beta1.81 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:MBIO) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.